Small Molecule Therapeutics
As well as peptides, Ferring is also specialised in researching and developing low molecular weight1 small molecule drugs Ferring’s small molecule technology allows drug and target discovery in non-peptide and peptidomimetic compounds such as g-protein coupled receptor (GCPR) agonists2 and protease inhibitors3.
Ferring markets a number of small molecules including PENTASA. [url: "http://pentasaus.com/" ] In addition, a recent small molecule success by Ferring was the discovery of a vasopressin V2 agonist, the compound FE 106483, which is designed to treat nocturia and is currently in phase II clinical trials.